Adverum_Primary_Medium.png
Adverum Issues Statement Regarding Upcoming Annual Meeting of Stockholders
May 10, 2021 08:15 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies Inc. (“Adverum”) (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare...
Adverum_Primary_Medium.png
Adverum Reports First Quarter 2021 Results
May 06, 2021 16:00 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021
May 01, 2021 15:26 ET | Adverum Biotechnologies, Inc.
-- Long-term durability and maintained efficacy; sustained robust aflibercept protein expression observed -- -- 60% of patients injection free beyond 1 year following 2 x 10^11 single dose -- ...
Adverum_Primary_Medium.png
Adverum Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema
April 28, 2021 16:01 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony...
Adverum_Primary_Medium.png
Adverum Files Investor Presentation Highlighting Significant Strategic Progress and Purpose-Built Board to Oversee Stockholder Value Creation
April 22, 2021 16:15 ET | Adverum Biotechnologies, Inc.
Urges Stockholders to Vote the WHITE Proxy Card “FOR” ALL of Adverum’s Three Highly Qualified, Diverse and Independent Directors: Dawn Svoronos, Reed V. Tuckson, M.D. and Thomas Woiwode, Ph.D. ...
Adverum Mails Letter to Stockholders Highlighting World-Class Board of Directors Overseeing Successful ADVM-022 Commercial Launch
April 21, 2021 08:00 ET | Adverum Biotechnologies, Inc.
Sonic’s Nominees Lack Experience and Qualifications to Advance Adverum’s Commercialization Progress or Deliver Global Access to Vision-Saving Gene Therapy Urges Stockholders to Vote the WHITE Proxy...
Adverum_Primary_Medium.png
Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021 
April 16, 2021 08:05 ET | Adverum Biotechnologies, Inc.
-- Adverum to host webcast with key opinion leaders on Sunday, May 2, 2021 at 7:00 AM PT --  REDWOOD CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM),...
Adverum Files Definitive Proxy Materials and Mails Letter to Stockholders Detailing Strength of Team and Acceleration Toward Commercialization of ADVM-022
April 15, 2021 08:00 ET | Adverum Biotechnologies, Inc.
Urges Stockholders to Vote the WHITE Proxy Card “FOR ALL” of Adverum’s Three Highly Qualified, Diverse and Independent Directors: Dawn Svoronos, Reed Tuckson, M.D. and Tom Woiwode, Ph.D. Annual...
Adverum_Primary_Medium.png
Adverum Announces Senior Appointments for Patient Access and Clinical Operations as ADVM-022 Advances Toward Global Phase 3 Trials
March 30, 2021 09:00 ET | Adverum Biotechnologies, Inc.
-- Anand Reddi appointed vice president, patient advocacy, access, and digital innovation -- -- Bill Tan, PharmD, appointed vice president, clinical operations program lead -- REDWOOD CITY,...
Adverum_Primary_Medium.png
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 18, 2021 16:00 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare...